BioSpace News Archive

AstriVax is pleased to announce that it has been selected for funding by Flanders Innovation & Entrepreneurship.

IRADIMED CORPORATION announced that its Board of Directors approved a special cash dividend of $0.48 per share and the initiation of a regular quarterly dividend on the Company’s outstanding common stock.

Plexium, Inc. (Plexium), a leading next-generation targeted protein degradation company, today reported that the first subjects have been dosed in a Phase 1 clinical study of orally administered PLX-4545, a potent and selective molecular glue degrader of IKZF2, a classically undruggable transcription factor also known as Helios.